(Morristown, NJ – October 15, 2021) – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids, is pleased to announce that Taggart McGurrin, Neumentum’s Chief Business Officer, has won the Rising Star Award from the Life Sciences Leaders & Stars Awards by Informa Connect. This award recognizes and celebrates achievement across three key categories within the life sciences accounting and finance community – Innovation, Achievement, and Leadership. McGurrin was chosen and recognized as a forward-thinking industry leader who is moving the needle and driving progress within the broader life sciences community.

“Tagg is at the heart of Neumentum, energizing and integrating all we do and accomplish,” says Scott Shively, Chief Executive Officer and Co-Founder at Neumentum. “He demonstrates tireless energy, dedication, and desire to grow and has played a vital role in our growth and success with the positive demeanor and team approach that exemplifies Neumentum’s collaborative culture.”

McGurrin was recently promoted from Director of Finance & Business Development to Chief Business Officer and has been appointed corporate secretary by Neumentum’s Board of Directors. He holds a BS/MBA dual-degree in Accounting from the University of Scranton, a Juris Doctor degree from Temple University James E. Beasley School of Law, and is a Certified Public Accountant.

“Tagg has worked hand in glove with the Neumentum team to raise over $40mm, complete two licensing deals, and build out the corporate financial, accounting and legal structure of the company,” said Dr. Joseph Pergolizzi, Executive Chairman & Co-Founder at Neumentum. “Tagg has executed cross functionally with great results and style. His outstanding performance and work ethic clearly qualify him for this award and recognition.”

About Neumentum: Addressing a National Health Emergency
Neumentum, based in Summit NJ, is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the risks of abuse, misuse and diversion seen with opioids, or opioid-induced side effects including potentially life-threatening respiratory depression.

Opioid use is considered a critical public health concern in the US. In 2018, 9.9 million people over age of 12 reported misusing prescription opioid pain relievers1, and opioids were involved in 46,802 overdose deaths.2 Opioids also account for over 305,000 emergency department visits annually for non-fatal overdoses.3 Despite these staggering statistics, and the frequently reported opioid-induced side effects such as nausea, vomiting, constipation and somnolence, 168 million prescriptions – over 51 prescriptions per 100 Americans – were written for opioids in 2018.4

Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion.

Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.

# # #

Scott Shively
CEO & Co-founder


[1] SAMSHA, Key Substance Use and Mental Health Indicators in the US: Results from the 2018 National Survey on Drug Use and Health. P13, Fig 10.

[2] Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL. MMWR Morb Mortal Wkly Rep 2020; 69:290–297

[3] Vivolo-Kantor AM, Hoots BE, Scholl L, et al. MMWR Morb Mortal Wkly Rep 2020;69:371–376

[4] www.cdc.gov/drugoverdose/maps/rxrate-maps.html, accessed 16 Jul 2020